HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B
Open Access
- 28 February 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 56 (12) , 1695-1703
Abstract
Background. The roles of single-nucleotide polymorphisms (SNPs) at HLA-DP and IL28B loci on hepatitis B surface antigen (HBsAg) seroclearance in chronic hepatitis B (CHB) infection are unknown. Methods. We compared the HLA-DP (rs3077, rs9277378, rs3128917) and IL28B (rs12979860, rs8099917) polymorphisms of 203 CHB patients achieving spontaneous HBsAg seroclearance with 203 age- and sex-matched CHB patients without HBsAg seroclearance (controls). Results. The distribution of all 5 polymorphisms was in Hardy-Weinberg equilibrium. HLA-DP rs3077 was associated with HBsAg seroclearance in terms of allelic frequency (minor allele A vs major allele G, P = .035; odds ratio [OR], 0.699; 95% confidence interval [CI], .501–.976) and genotypic frequency (AA vs GG/GA, P = .014; OR, 0.295; 95% CI, .106–.822). Haplotype analysis of HLA-DP polymorphisms showed haplotype block GAT (rs3077/rs9277378/rs3128917) to be associated with HBsAg seroclearance (OR, 2.17; 95% CI, 1.06–4.45, P = .034). Influence of HLA-DP polymorphisms on HBsAg seroclearance was more pronounced in younger patients, with the OR for rs3077 minor allele A and haplotype block GAT being 0.560 and 2.68, respectively, among patients aged .05). Conclusions. Specific SNPs in HLA-DP and IL28B locus, through individual and haplotype analysis, were associated with a higher chance of HBsAg seroclearance in CHB infection. The associations were more prominent in patients with HBsAg seroclearance at a younger age.Keywords
This publication has 38 references indexed in Scilit:
- A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearanceHepatology, 2012
- Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen SeroconvertersGastroenterology, 2011
- Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical SafetyAmerican Journal of Gastroenterology, 2011
- Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡Hepatology, 2010
- Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up StudyGastroenterology, 2010
- Durability of Peginterferon Alfa-2B Treatment at 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis BHepatology, 2010
- Clearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma in A Cohort Chronically Infected With Hepatitis B VirusHepatology, 2010
- Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2aGastroenterology, 2009
- HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular CarcinomaGastroenterology, 2008
- HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspectsHepatology, 2004